Pfizer embraces stem cells

Big pharma's interest in linkurl:stem cell research;http://www.the-scientist.com/blog/display/54900/ is picking up speed. Pharmaceutical giant Pfizer is expanding its research into the technology and plans to open a second regenerative medicine unit in Cambridge, UK, this November, Reuters linkurl:reported;http://www.reuters.com/article/reutersEdge/idUSTRE48MBY020080923?sp=true yesterday. Pfizer isn't the only one. In July, GlaxoSmithKline entered a linkurl:5-year, $25 million collaboration;ht

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Big pharma's interest in linkurl:stem cell research;http://www.the-scientist.com/blog/display/54900/ is picking up speed. Pharmaceutical giant Pfizer is expanding its research into the technology and plans to open a second regenerative medicine unit in Cambridge, UK, this November, Reuters linkurl:reported;http://www.reuters.com/article/reutersEdge/idUSTRE48MBY020080923?sp=true yesterday. Pfizer isn't the only one. In July, GlaxoSmithKline entered a linkurl:5-year, $25 million collaboration;http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10089.htm with the Harvard Stem Cell Institute. In the spring, Pfizer opened a regenerative medicine unit in Cambridge, Massachusetts, focusing on stem cells for cardiac disorders and cancer, according to the linkurl:company's Web site.;http://www.pfizer-regenerativemedicine.com/locations/index.php The new UK site will eventually house 60 scientists and research will focus on age-related and degenerative and nervous system disorders. While Pfizer's stem cell research policy does not rule out the use of embryonic stem cells, the company is also extremely interested in induced pluripotent stem (iPS) cells, John McNeish, head of the Massachusetts operation, told Reuters at the World Stem Cell Summit, held this week in Madison, Wisconsin. In June, Pfizer also entered a linkurl:$3 million partnership;http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&newsId=20080623005677&newsLang=en with EyeCyte, Inc., a California company whose technology uses blood and bone marrow progenitor cells to treat retinal diseases.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Andrea Gawrylewski

    This person does not yet have a bio.
Share
Image of a woman in a microbiology lab whose hair is caught on fire from a Bunsen burner.
April 1, 2025, Issue 1

Bunsen Burners and Bad Hair Days

Lab safety rules dictate that one must tie back long hair. Rosemarie Hansen learned the hard way when an open flame turned her locks into a lesson.

View this Issue
Conceptual image of biochemical laboratory sample preparation showing glassware and chemical formulas in the foreground and a scientist holding a pipette in the background.

Taking the Guesswork Out of Quality Control Standards

sartorius logo
An illustration of PFAS bubbles in front of a blue sky with clouds.

PFAS: The Forever Chemicals

sartorius logo
Unlocking the Unattainable in Gene Construction

Unlocking the Unattainable in Gene Construction

dna-script-primarylogo-digital
Concept illustration of acoustic waves and ripples.

Comparing Analytical Solutions for High-Throughput Drug Discovery

sciex

Products

Green Cooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Thermo Fisher Logo
Singleron Avatar

Singleron Biotechnologies and Hamilton Bonaduz AG Announce the Launch of Tensor to Advance Single Cell Sequencing Automation

Zymo Research Logo

Zymo Research Launches Research Grant to Empower Mapping the RNome

Magid Haddouchi, PhD, CCO

Cytosurge Appoints Magid Haddouchi as Chief Commercial Officer